secwatch.observer — SEC 8-K summary
======================================

Issuer:     Editas Medicine, Inc. (EDIT)
CIK:        0001650664
Form:       8-K
Filed at:   2023-06-09T23:59:59+00:00
Accession:  0001558370-23-010931
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Editas Medicine reports positive EDIT-301 data; two SCD patients reach normal hemoglobin
--------------------------------------------------------------------------------

- Patient 1 (SCD) total hemoglobin 16.4 g/dL at 5 months, maintained at 10-month follow-up; fetal Hb 45.4%.
- Patient 2 (SCD) total hemoglobin 12.7 g/dL at 5 months, fetal Hb 51.3% at 6-month follow-up.
- All four RUBY patients free of vaso-occlusive events post-infusion; no serious adverse events from EDIT-301.
- First EdiTHAL beta thalassemia patient achieved 34.9% fetal Hb (4 g/dL total Hb) at 1.5 months.
- Company on track to dose 20 RUBY patients by year-end; data presented at EHA Congress.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1650664/000155837023010931/0001558370-23-010931-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1650664/000155837023010931/edit-20230609x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-010931

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer